Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. (3rd August 2019)

• Record Type: Journal Article
• Authors: Megna, Matteo; Di Costanzo, Luisa; Argenziano, Giuseppe; Balato, Anna; Colasanti, Paola; Cusano, Francesco; Galluccio, Antonia G.; Gambardella, Alessio; Lembo, Serena; Mozzillo, Raffaele; Scotto Di Luzio, Genoveffa; Fabbrocini, Gabriella; Balato, Nicola
• Is Part Of: Expert opinion on biological therapy. Volume 19:Number 8(2019)
• Page Start: 855
• Page End: 861
• Publication Date: 2019-08-03
• Subjects: Anti-IL-17 -- biologic drugs -- PASI -- psoriasis -- real life -- secukinumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2019.1622678
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Background : Long term data on the real-life use of secukinumab are scant. The aim of this study was to investigate the real-life effectiveness, safety and treatment persistence of secukinumab in patients with moderate-to-severe psoriasis. Research design and methods : This 84-week, multicenter (n = 7) retrospective study analyzed data from patients who initiated and received at least 6 months of secukinumab treatment between June 2016 and June 2018 in the Campania region of Italy. Patient demographic and treatment characteristics, duration of treatment and reasons for discontinuation as well as Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores were assessed. Results : 324 patients (63% male, mean age 50.2 years) were enrolled and received a mean 11.7 months of secukinumab treatment. Overall, 9.5% discontinued secukinumab, including 5.2% who discontinued due to secondary inefficacy and 1.8% due to adverse events. PASI, BSA and DLQI scores were significantly improved from baseline at every follow-up visit (p < 0.001) and mean PASI decreased from 15.3 ± 6.3 at baseline to 0.5 ± 1.0 at week 84. Secukinumab had comparable effectiveness in biologic naïve and non-naïve patients. Conclusions : This study confirmed the effectiveness and safety of secukinumab in real-world patients with psoriasis.